Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres

Haemophilia

Volumn 18, Issue 1, 2012, Pages 63-68

  Ragni, M V ^a   Fogarty, P J ^b   Josephson, N C ^c   Neff, A T ^d   Raffini, L J ^e   Kessler, C M ^f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Central venous catheter; Children; Circumcision; Haemophilia A; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BUDGET; CATHETER COMPLICATION; CENTRAL VENOUS CATHETERIZATION; CHILDHOOD DISEASE; CIRCUMCISION; DISEASE SEVERITY; GINGIVA BLEEDING; HEALTH SURVEY; HEMARTHROSIS; HEMOPHILIA A; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MUSCLE HEMATOMA; NEWBORN; ORAL BLEEDING; PERSONNEL SHORTAGE; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOFT TISSUE DISEASE;

CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; MALE; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; UNITED STATES;

EID: 80053190308     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02554.x     Document Type: Article

References (22)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC Recommendation Concerning Prophylaxis: Regular Administration of Clotting Factor Concentrate to Prevent Bleeding (#179). Available at
3. Ragni MV, Hord JD, Blatt J. Central venous catheter infection in hemophiliacs undergoing prophylaxis or immune tolerance. Haemophilia 1997; 3: 90-5.
4. Ragni MV, Journeycake JM, Brambilla D. Tissue plasminogen activator to prevent central venous access device infection: A systematic review of CVAD thrombosis, infection, and thromboprophylaxis. Haemophilia 2008; 14: 30-8.
5. Jeng M, O'Brien M, Wong W et al. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia. Haemophilia 2009; 15: 1272-80.
6. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
7. Hay CR. The epidemiology of factor VIIII inhibitors. Haemophilia 2006; 12(Suppl. 6): 23-8.
8. Ragni MV, Ojeifo O, Hill K et al. Risk factors for inhibitor formation in hemophilia: A prevalent case-control study. Haemophilia 2009; 15: 1074-82.
9. Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J. Home-based infusion therapy an hospitalization for bleeding complications among males with hemophilia. Haemophilia 2001; 7: 198-206.
10. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
11. Carcao M, Chambost H, Ljung R. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia 2010; 16(Suppl. 2): 4-9.
12. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 256-62.
13. Medical product safety. Healthy People 2010 2003; 17: 3-19. Available at
14. Link R, Kindzelski AL, Cines DB et al. 2009 Hemostasis and thrombosis state of the science symposium. In preparation.
15. Ragni MV, Fogarty P, Josephson N, Neff A, Raffini L, Kessler C. The Hemophilia Inhibit Study: A Prospective Randomized Trial of rFVIII to Prevent Inhibitor Formation in Children with Hemophilia. Chicago, IL, Hemophilia Thrombosis Research Society of North America (HTRS), April 16-18, 2010(abstract).
16. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
17. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
18. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
19. Kulkarni R, Soucie JM, Lusher L et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with hemophilia diagnosed before the age of 2years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009; 15: 1281-90.
20. Mahlangu JN. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia 2009; 15: 135-41.
21. Rodriguez V, Titapiwatanakun R, Moir C, Schmidt KA, Pruthi RK. To circumcise or not to circumcise. Circumcision in patients with bleeding disorders. Haemophilia 2010; 16: 272-6.
22. Ljung R, Chambost H, Stain AM, DiMichele D. Haemophilia in the first years of life. Haemophilia 2008; 3: 188-95.